
==== Front
Int J Cardiol Cardiovasc Risk Prev
Int J Cardiol Cardiovasc Risk Prev
International Journal of Cardiology. Cardiovascular Risk and Prevention
2772-4875
Elsevier

S2772-4875(24)00086-2
10.1016/j.ijcrp.2024.200321
200321
Research Paper
Demographics and mortality trends of valvular heart disease in older adults in the United States: Insights from CDC-wonder database 1999–2019
Ali Eman a
Mashkoor Yusra a
Latif Fakhar a
Zafrullah Fnu b
Alruwaili Waleed c
Nassar Sameh d
Gonuguntla Karthik d
Thyagaturu Harshith d
Kawsara Mohammad d
Daggubati Ramesh d
Sattar Yasar d
Asghar Muhammad Sohaib sohaib_asghar123@yahoo.com
e⁎
a Dow University of Health Sciences, Karachi, Pakistan
b Department of Cardiology, Ascension Borgess Hospital/Michigan State University, MI, USA
c Department of Internal Medicine, West Virginia University, Morgantown, WV, USA
d Department of Cardiology, West Virginia University, Morgantown, WV, USA
e Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
⁎ Corresponding author. sohaib_asghar123@yahoo.com
17 8 2024
9 2024
17 8 2024
22 2003213 7 2024
15 8 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Background

Valvular heart disease (VHD) represents a spectrum of cardiac conditions, including valvular stenosis, valvular regurgitation, or mixed lesions affecting single or multiple valves. The severity of VHD has emerged as a major cause of cardiovascular (CV) morbidity and mortality among the older population in the United States (U.S).

Objective

To evaluate temporal trends in mortality associated with VHD in the elderly U.S population between 1999 and 2019.

Methods

We utilized the CDC WONDER database for VHD mortality in adults ≥75 from 1999 to 2019, using ICD-10 codes. Age-adjusted mortality rates (AAMR) per 100,000 people with associated annual percentage change (APC) were calculated. Joinpoint regression was used to assess the overall trends and trends for demographic, geographic, and type of valvular disease subgroups.

Results

A total of 666,765 VHD deaths in older adults from 1999 to 2019 was identified, with an initial decline in AAMR until 2007 with an APC: 0.62, 95 % CI (−1.66-0.33), stability until 2014, and a significant decrease until 2019 (APC: 1.47, 95 % CI [-2.24-1.04], P < 0.0001). Men consistently had higher AAMRs compared to women (overall AAMR men: 173.6; women: 138.2). The AAMRs were found to be highest in the White (166.5), followed by American Indian or Alaska Native population at (93.8) Hispanic or Latino at (80.7), Black or African American populations at (74.1) and lastly Asian or Pacific Islander (73.4). Non-metropolitan areas manifested higher AAMRs for deaths related to VHD than metropolitan areas (overall AAMRs 160.5 vs 149.5) respectively. State-wide AAMRs varied, with the highest in Vermont at 324.2 (95 % CI [313.0–335.4], P < 0.0001) and the lowest in Mississippi at 88.0 (95 % CI [85.0–91.0], P < 0.0001). Non-rheumatic and aortic valve disorders in adults ≥75 years had higher mortality rates compared to rheumatic or mitral valve conditions in those <75 years.

Conclusion

Our study showed a decline in U.S. VHD mortality from 1999 to 2019 but found persistent disparities by gender, race, age, region, and VHD type. Targeted policies for prevention and early diagnosis are needed to address these inequalities.

Keywords

Valvular heart disease
Epidemiology
Mortality
Trend
AAMR
Handling Editor: D Levy
==== Body
pmc1 Introduction

Valvular heart disease (VHD) is a group of cardiac conditions that involve abnormalities, such as stenosis, regurgitation, or mixed lesions of both, in one or more heart valves, including the mitral, tricuspid, aortic, and pulmonary valves [1]. These diseases place a hemodynamic burden on the ventricles, eventually manifesting as ventricular muscle dysfunction and congestive heart failure (CHF) [2]. As such, valvular heart diseases are a progressively growing cause of cardiovascular (CV) morbidity and mortality in the United States (U.S).

Life expectancy in the U.S is increasing, and it is estimated that the population aged over 80 years will triple, growing from 11.4 million in 2010 to 32.4 million by 2050 [3]. The prevalence of VHD increases with age, resulting in a growing concern about an increase in projected valvar heart disease burden in the coming decades. Around 2.5 % of the American population suffered from valvular heart disease in 2014, which was more common in the elderly [1]. Furthermore, about 13 % of people born before 1943 have VHD [1]. With such staggering statistics, the efforts to mitigate the public health impact of VHD must be accelerated.

Effective management of VHD in elderly individuals requires a collaborative multidisciplinary team involving anaesthesiologists, interventional and imaging cardiologists, and cardiac surgeons. Historically, surgery has been the cornerstone of the treatment; however, postoperative clinical outcomes are heavily influenced by concomitant comorbidities, such as chronic kidney disease (CKD) and diabetes mellitus (DM) [4]. Minimally invasive approaches have been introduced to alleviate the shortcomings of surgery, like transcatheter valve repairs, which have better prognoses and fewer complications [5]. Recently, there have been notable shifts in healthcare practices, diagnostic capabilities, and therapeutic interventions. Understanding how these changes have influenced the demographics and outcomes of VHD-related mortality is of paramount importance for healthcare providers, researchers, and policymakers to provide optimal care for this vulnerable population. Consequently, this study was conducted with the objective of retrospectively evaluating the temporal trends in mortality associated with VHD in the elderly population of the U.S between 1999 and 2019.

2 Methods

2.1 Data sources

Our analysis involved the data from Centers for Disease Control and Prevention, Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Multiple Cause-of-Death Public Use Record death certificates were used to analyze deaths in individuals ≥75 years of age in which valvular heart disease was mentioned as either contributing or underlying cause of death [6,7]. We used the following International Classification of the Diseases, Tenth Revision (ICD-10) codes to identify valvular heart disease-related cases: I08.0 (Disorders of both mitral and aortic valves); I08.1 (Disorders of both mitral and tricuspid valves); I08.2 (Disorders of both aortic and tricuspid valves); I08.3 (“Combined disorders of mitral, aortic and tricuspid valves”); I08.8 (“Other multiple valve diseases”); I08.9 (“Multiple valve disease, unspecified”); I34.0 (“Mitral (valve) insufficiency”); I34.1 (“Mitral (valve) prolapse”); I34.2 (“Nonrheumatic mitral (valve) stenosis”); I34.8 (“Other nonrheumatic mitral valve disorders”); I34.9 (“Nonrheumatic mitral valve disorder, unspecified”); I35.0 (“Aortic (valve) stenosis”); I35.1 (“Aortic (valve) insufficiency”); I35.2 (“Aortic (valve) stenosis with insufficiency”); I35.8 (“Other aortic valve disorders”); I35.9 (“Aortic valve disorder, unspecified”); I36.0 (“Nonrheumatic tricuspid (valve) stenosis”); I36.1 (“Nonrheumatic tricuspid (valve) insufficiency”); I36.2 (“Nonrheumatic tricuspid (valve) stenosis with insufficiency”); I36.8 (“Other nonrheumatic tricuspid valve disorders”); I36.9 (“Nonrheumatic tricuspid valve disorder, unspecified”); I37.0 (“Pulmonary valve stenosis”); I37.1 (“Pulmonary valve insufficiency”); I37.2 (“Pulmonary valve stenosis with insufficiency”); I37.8 (“Other pulmonary valve disorders”); I37.9 (“Pulmonary valve disorder, Unspecified”) [6,7].

2.2 Ethics committee

Institutional review board approval was not sought since the data was publicly available, anonymized government data. Additionally, the study was conducted in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.

2.3 Data extraction

The number of valvular heart disease-related deaths and population size were extracted from 1999 to 2019. The data on age, sex, race and ethnicity, region, and state were also abstracted. We then selected patients aged ≥75 years and divided them into 10-year age groups. Thereafter, we categorized older patients based on sex and studied individual mortality trends for both sexes. For race, patients were stratified into White, Black, Hispanic, Asian/Pacific Islander, and American Indian/Alaskan Native. In addition, a sub-group analysis for rheumatic versus non-rheumatic valvular disorders and aortic versus mitral valvular diseases was also performed. Moreover, mortality trends were also compared with younger patients with valvular disorders by stratifying patients into 2 groups: patients aged ≥75 years and patients aged <75 years. The population was further stratified into metropolitan and non-metropolitan areas using the National Center for Health Statistics Urban-Rural Classification Scheme [8].

2.4 Statistical analysis

The number of valvular heart disease-related deaths was divided by the total corresponding population to calculate the crude death rates for individual years. The annual mortality rates were calculated per 100,000 population, and their corresponding 95 % confidence intervals (CIs) were also determined [9]. The mortality rates were adjusted for age by standardizing to the year 2000 US standard population. Temporal trends in mortality were examined to deduce changes in slope using Joinpoint Regression Program version 4.7.0.0, which models consecutive linear segments on a log scale connected by Joinpoints, where the segments converge [10]. Annual percentage changes (APC) and Average Annual Percentage Changes (AAPCs) were calculated, with their corresponding 95 % CIs for the line segments linking a Joinpoint. Slopes were considered increasing or decreasing if the estimated slope differed significantly from zero. The statistical significance was determined by 2-sided t-testing (P = 0.05).

3 Results

3.1 Annual trends for VHD-related AAMR

Between 1999 and 2019, a total of 666,765 VHD-related deaths occurred in the study population (Table 1). Over the years, a decline in AAMRs for VHD-related deaths among older adults has been observed, with AAMR 158.8 (95 % CI: 156.9–160.8) in 1999 and 142.6 (95 % CI: 141.0–144.1) in 2019. Notably, overall AAMR for VHD-related deaths exhibited a significant reduction from 1999 to 2007 with an APC of −0.62 [95 % CI: 1.66 to −0.33]. Following this period, AAMRs remained stable between 2007 and 2014 (APC: 0.21 [95 % CI: 0.11 to 1.23]). Subsequently, from 2014 to 2019, another significant decline in AAMRs was observed (APC: 1.47 [95 % CI: 2.24 to −1.04]). Demographic characteristics, including the number of deaths and AAMRs, with APCs and AAPCs among the elderly with VHD-related mortality, have been highlighted in Table 1, Table 2, and Supplementary Table 1.Table 1 Demographic characteristics of deaths due to valvular heart disease among the elderly in the USA from 1999 to 2019.

Table 1Variable	Death (n)	AAMR	
Overall	666,765	151.5 (151.1, 151.8)	
Sex	
Males	276,068	173.6 (172.9–174.2)	
Females	390,697	138.2 (137.8–138.6)	
Race/Ethnicity	
American Indian or Alaska Native	1576	93.8 (89.1, 98.4)	
Asian or Pacific Islander	10,290	73.4 (71.9, 74.8)	
Black or African American	24,476	74.1 (73.2, 75.1)	
White	608,575	166.5 (166.0, 166.9)	
Hispanics	20,851	80.7 (79.6, 81.8)	
Metropolitan/non-metropolitan	
Metropolitan	540,470	149.5 (149.1, 149.9)	
Non-metropolitan	126,295	160.5 (159.6, 161.3)	
Rheumatic/Non-Rheumatic Valve Disease	
Rheumatic Valve Disease	55,568	12.9 (12.8, 13.0)	
Non-Rheumatic Valve Disease	105,521	24.3 (24.1, 24.4)	
Aortic/Mitral Valve Disorder	
Aortic Valve Disorder	558,629	126.7 (126.3, 127)	
Mitral Valve Disorder	129,459	30.0 (29.8, 30.1)	
Younger than 75 Years/Older than 75 Years	
Younger than 75 Years	172,372	23.8 (23.7, 23.9)	
Older than 75 Years	666,765	1515.0 (1511.4, 1518.7)	

Table 2 Annual percentage changes (APCs) and average annual percentage changes (AAPCs) in valvular heart diseases- related mortality rate among the elderly in the USA from 1999 to 2019.

Table 2Variable	Trend Segment	Year Interval	APC (95 % CI)	AAPC (95 % CI)	
Overall	1	1999–2007	−0.62* (−1.66, −0.33)	−0.55* (−0.67, −0.45)	
2	2007–2014	0.21 (−0.11, 1.23)	
3	2014–2019	−1.47 (−2.24, −1.04)	
Men	1	1999–2006	−0.68* (−1.44, −0.29)	−0.51* (−0.62, −0.41)	
2	2006–2014	0.47* (0.17, 1.19)	
3	2014–2019	−1.83* (−2.43, −1.34)	
Women	1	1999–2015	−0.43 (−0.54, 0.39)	−0.62* (−0.77, −0.43)	
2	2015–2019	−1.36* (−3.09, −0.61)	
White	1	1999–2007	−0.42* (−1.43, −0.12)	−0.25* (−0.38, −0.16)	
2	2007–2014	0.57* (0.22, 1.66)	
3	2014–2019	−1.13* (−1.94, −0.65)	
Black or African American	1	1999–2009	−1.09 (−4.38, 1.33)	−0.49* (−0.83, −0.10)	
2	2009–2019	0.11 (−0.81, 3.41)	
American Indian or Alaska Native	1	1999–2011	1.29 (−0.13, 13.89)	−0.50 (−1.64, 1.12)	
2	2011–2019	−3.13* (−13.17,-0.82)	
Hispanic or Latino	1	1999–2019	−0.83* (−1.12, −0.49)	−0.83* (−1.12, −0.49)	
Asian or Pacific Islander	1	1999–2019	−1.25* (−1.67, −0.72)	−1.25* (−1.67, −0.72)	
Nonmetropolitan areas	1	1999–2015	0.33* (0.15, 1.17)	0.01 (−0.23, 0.28)	
2	2015–2019	−1.26* (−4.15, −0.02)	
Metropolitan area	1	1999–2007	−0.74* (−1.83, −0.44)	−0.65* (−0.77, −0.56)	
2	2007–2014	0.10 (−0.22, 1.12)	
3	2014–2019	−1.56* (−2.32, −1.11)	
Rheumatic Valve Disease	1	1999–2004	−5.38* (−7.63, −3.96)	−1.11* (−1.34, −0.91)	
2	2004–2012	−1.05 (−5.85, 0.44)	
3	2012–2017	0.83 (−1.56, 1.86)	
4	2017–2019	5.01* (2.01, 6.92)	
Non-Rheumatic Valve Disease	1	1999–2012	−4.77* (−5.16, −4.56)	−2.58* (−2.72, −2.44)	
2	2012–2017	2.42 (−4.75, 3.28)	
3	2017–2019	−0.32 (−2.02, 1.87)	
Mitral Valve Disorders	1	1999–2004	−5.50* (−7.40, −4.72)	−2.65* (−2.79, −2.50)	
2	2004–2012	−3.63* (−4.18, −2.12)	
3	2012–2019	0.61* (0.06, 1.38)	
Aortic Valve Disorders	1	1999–2006	−0.46* (−1.56, −0.07)	−0.38* (−0.49, −0.28)	
2	2006–2013	0.84* (0.47, 1.89)	
3	2013–2019	−1.71* (−2.18, −1.31)	
Younger than 75 Years	1	1999–2008	−3.09* (−3.88, −2.78)	−1.10* (−1.19, −0.99)	
2	2008–2012	1.4166 (−2.74, 1.38)	
3	2012–2019	1.72* (1.35, 2.36)	
Older than 75 Years	1	1999–2007	−0.6168* (−1.67, −0.33)	−0.54* (−0.66, −0.46)	
2	2007–2014	0.21 (−0.10, 1.20)	
3	2014–2019	−1.48* (−2.23, −1.03)	

3.2 VHD-related AAMR stratified by sex

Throughout the study, it was observed that older men consistently had higher AAMRs compared to older women (overall AAMR men: 173.6 [95 % CI: 172.9–174.2]; overall AAMR women: 138.2 [95 % CI: 137.8–138.6]). Specifically, in 1999, the AAMR for men was 180.1 (95 % CI: 176.5–183.7), which gradually decreased to 168.8 (95 % CI: 165.6–172.0) in 2006 (APC: 0.68 [95 % CI: 1.44 to −0.29]). However, this was followed by a slight increase until 2014 (APC: 0.47 [95 % CI: 0.17 to 1.19]). Subsequently, there was a notable steep decline in AAMRs from 2014 to 2019 (APC: 1.83 [95 % CI: 2.43 to −1.34]), and at the end of the study period, the AAMR of 163.4 (95 % CI: 160.8–166.0) was noted in men.

On the other hand, the AAMR for women in 1999 was 146.8 (95 % CI: 144.5–149.1), and after which there was a period of stability until 2015 (APC: 0.43 [95 % CI: 0.54 to 0.39). Subsequently, a statistically significant decrease was observed from 2015 to 2019 (APC: 1.36 [95 % CI: 3.09 to −0.61]), and at the end of the study period, the AAMR of women was 128.7 (95 % CI: 126.8–130.5) (Fig. 1 and Supplementary Table 2).Fig. 1 VHD-related mortality Trends in older adult population and stratified for sex in 1999–2019.

Fig. 1

3.3 VHD-related AAMR stratified by race/ethnicity

When stratified by race/ethnicity, variations in AAMRs for VHD-related deaths were evident. The AAMRs were found to be highest in the White population with a rate of 166.5 (95 % CI: 166.0–166.9), followed by American Indian or Alaska Native population at 93.8 (95 % CI: 89.1–98.4), Hispanic or Latino at 80.7 (95 % CI: 79.6–81.8), and Black or African American populations at 74.1 (95 % CI: 73.2–75.1). The lowest AAMRs were observed in the Asian or Pacific Islander populations, with a rate of 73.4 (95 % CI: 71.9–74.8).

In brief, the AAMRs for American Indian or Alaska Native populations remained stable from 1999 to 2011 (APC: 1.29 [95 % CI: 0.13 to 13.89]). This was followed by a steep decline from 2011 to 2019 (APC: 3.13 [95 % CI: 13.17 to −0.82]), while that of Asian or Pacific Islander and Hispanic or Latinos populations significantly declined between 1999 and 2019 (Asian or Pacific Islander: APC: 1.25 [95 % CI: 1.67 to −0.72]; Hispanic or Latinos: APC: 0.83 [95 % CI: 1.12 to −0.49]). With respect to Black or African American populations, AAMRs remained stable from 1999 to 2009 (APC: 1.09 [95 % CI: 4.38 to 1.33]). Similarly, from 2009 to 2019, another period of stability was observed (APC: 0.11 [95 % CI: 0.81 to 3.41]). A steady decline in AAMRs was observed among white individuals from 1999 to 2007 (APC: 0.42 [95 % CI: 1.43 to −0.12]). This was followed by a slight increase until 2014 (APC: 0.57 [95 % CI: 0.22 to 1.66]), after which another significant decline was noted from 2014 to 2019 (APC: 1.13 [95 % CI: 1.94 to −0.65]) (Fig. 2, Supplementary Table 3).Fig. 2 VHD-related mortality Trends in older adult population stratified for differential racial groups in 1999–2019.

Fig. 2

3.4 VHD-related AAMR stratified by geographic region

In a consistent pattern through the majority of the study period, nonmetropolitan areas manifested higher AAMRs for deaths related to VHD than metropolitan areas, with overall AAMRs of 160.5 (95 % CI: 159.6–161.3) and 149.5 (95 % CI: 149.1–149.9), respectively. Furthermore, the AAMRs of nonmetropolitan areas increased from 1999 to 2015 (APC: 0.33 [95 % CI: 0.15 to 1.17]), which was then followed by a steady decline from 2015 to 2019 (APC: 1.26 [95 % CI: 4.15 to −0.02]). On the contrary, AAMRs of metropolitan areas exhibited a steady decline from 1999 to 2007 (APC: 0.74 [95 % CI: 1.83 to −0.44]). This was followed by a period of stability until 2014 (APC: 0.10 [95 % CI: 0.22 to 1.12]), and finally, from 2014 to 2019, another significant decline in AAMRs was observed (APC: 1.56 [95 % CI: 2.32 to −1.11]) (Fig. 3, and Supplementary Table 4).Fig. 3 VHD-related mortality trends in older adult population residing in metropolitan vs. non-metropolitan areas in 1999–2019.

Fig. 3

A significant disparity in VHD-related AAMRs has been observed on the state level, with the figures spanning from 88.1 (95 % CI: 85.1–91.1) in Mississippi to 324.6 (95 % CI [313.4, 335.8]) in Vermont. It is important to highlight that the states ranked in the top 90th percentile for AAMRs namely, Iowa, Alaska, Idaho, Pennsylvania, Minnesota, Maine, New Hampshire, Washington, Oregon, and Vermont, had approximately more than double the AAMRs compared with states that are ranked in the lower 10th percentile, namely, Arkansas, New Mexico, Louisiana, District of Columbia, Nevada, Arizona, Kentucky, Utah (see Fig. 4, and Supplementary Table 5).Fig. 4 VHD-related mortality trends in older adult population stratified across 50 States in 1999–2019.

Fig. 4

3.5 VHD-related AAMR stratified by category of VHD

Throughout most of the study period, deaths related to VHDs were more frequent in non-rheumatic VHDs compared to rheumatic VHDs, with overall AAMRs of 24.3 (95 % CI: 24.1–24.4) and 12.9 (95 % CI: 12.8–13.0), respectively. Moreover, the AAMRs of non-rheumatic VHDs declined from 1999 to 2012 (APC: 4.77 [95 % CI: 5.16 to −4.56]), followed by periods of stability from 2012 to 2017 (APC: 2.42 [95 % CI: 4.75 to 3.28]) and 2017 to 2019 (APC: 0.32 [95 % CI: 2.02 to 1.87]). Similarly, AAMRs for rheumatic VHDs experienced a significant decline from 1999 to 2004 (APC: 5.38 [95 % CI: 7.63 to −3.96]), followed by stable rates from 2004 to 2012 (APC: 1.05 [95 % CI: 5.85 to 0.44]) and from 2012 to 2017 (APC: 0.83 [95 % CI: 1.56 to 1.86]). However, from 2017 to 2019, there was a notable increase in AAMRs for rheumatic VHDs (APC: 5.01 [95 % CI: 2.01 to 6.92]) (Fig. 5, and Supplementary Table 6).Fig. 5 Valvular Heart Disease-related mortality Trends in older adult population for rheumatic vs. non-rheumatic valvular diseases in 1999–2019.

Fig. 5

Aortic valve disorders (AVDs) have been the leading cause of VHD-related deaths throughout the study period in a consistent pattern as compared to mitral valve disorders (MVDs) with overall AAMRs of 126.7 (95 % CI: 126.3–127.0) and 30.0 (95 % CI: 29.8–30.1), respectively. The AAMRs of AVDs decreased from 1999 to 2006 (APC: 0.46 [95 % CI: 1.56 to −0.07]), followed by a steady incline from 2006 to 2013 (APC: 0.84 [95 % CI: 0.47 to 1.89]), and then a steep decline from 2013 to 2019 (APC: 1.71 [95 % CI: 2.18 to −1.31]). Similarly, AAMRs of MVDs exhibited a significant decline from 1999 to 2004 (APC: 5.50 [95 % CI: 7.40 to −4.72]) and 2004 to 2012 (APC: 3.63 [95 % CI: 4.18 to −2.12]). However, from 2012 to 2019, a significant incline in AAMRs was observed for MVDs (APC: 0.61 [95 % CI: 0.06 to 1.38]) (Fig. 6, and Supplementary Table 7).Fig. 6 Valvular Heart Disease-related mortality Trends in older adult population for mitral vs. aortic valvular diseases in 1999–2019.

Fig. 6

3.6 VHD-related AAMR stratified by age

In a consistent pattern, individuals aged 75 years and older manifested higher crude mortality rates for deaths related to VHD compared to those younger than 75 years, with an overall crude mortality rate of 1515.0 (95 % CI: 1511.4–1518.7) and 23.8 (95 % CI: 23.7–23.9), respectively. Furthermore, the crude death rate of the older age group decreased from 1999 to 2007 (APC: 0.61 [95 % CI: 1.67 to −0.33]), followed by a period of stability from 2007 to 2014 (APC: 0.21 [95 % CI: 0.10 to 1.20]) and then another significant decline from 2014 to 2019 (APC: 1.48 [95 % CI: 2.23 to −1.03]). In contrast, crude mortality rate of the younger age group exhibited a steep decline from 1999 to 2008 (APC: 3.09 [95 % CI: 3.88 to −2.78]), followed by a period of stability until 2012 (APC: 1.41 [95 % CI: 2.74 to 1.38]) and finally, from 2012 to 2019, a significant increase in crude death rate was noted (APC: 1.72 [95 % CI: 1.35 to 2.36]) (Fig. 7, and Supplementary Table 8).Fig. 7 Valvular Heart Disease-related mortality Trends for Different Age Groups in 1999–2019.

Fig. 7

4 Discussion

VHD poses a significant global public health challenge. Many parts of the world are still dealing with the negative outcomes of untreated rheumatic heart disease, a condition that can be largely prevented through prompt diagnosis and treatment. Additionally, middle- and high-income countries are witnessing an increase in the prevalence of calcific aortic and mitral diseases, partly due to an aging population. This public health issue is further complicated by high rates of infective endocarditis (IE), which results in substantial morbidity and mortality. Notably, research on VHD has not given adequate attention to considerations of gender, race, ethnicity, and geographical variations [11].

In this extensive 20-year analysis of nationwide mortality data obtained from the CDC, we have uncovered several noteworthy findings. Firstly, there was an initial period of decline in mortality rates related to VHD from 1999 to 2007, followed by a period of stability until 2014, and subsequently, a notable reduction in mortality from 2014 to 2019. Secondly, males exhibited higher VHD-related mortality rates compared to females consistently throughout the study. Thirdly, among the various racial and ethnic groups examined in this research, White adults displayed the highest AAMR for VHD. Fourthly, significant variations were observed between different regions, with states in the top 90th percentile, such as Pennsylvania, New Hampshire, Washington, Oregon, and Vermont, reporting AAMRs more than twice those of states in the lower 10th percentile, including Mississippi, Georgia, Alabama, Arkansas, and New Mexico. Additionally, non-metropolitan areas consistently exhibited higher mortality rates compared to metropolitan areas. Moreover, increased mortality rates were observed for non-rheumatic VHDs and AVDs when compared to rheumatic and MVDS, respectively. Finally, we also observed lower mortality rates associated with VHDs in the younger population (<75 years) when compared to their older counterparts (≥75 years). These findings hold substantial implications for public health policy.

The decrease in VHD-related deaths aligns with the progress made in assessing, identifying, and managing this population over the past twenty years. Notably, advancements such as enhanced genetic screening and risk factors stratification, including personal and family history, along with Artificial Intelligence-enhanced ambulatory electrocardiographic monitoring, echocardiography, computed tomography, and cardiac magnetic resonance imaging, have led to improved diagnostics and risk assessment [[12], [13], [14], [15]]. Consequently, VHD is being diagnosed more frequently but with reduced clinical severity in older adults, likely due to better clinical recognition [16].

Furthermore, therapeutic progress in VHD management, including newer approaches for percutaneous and surgical valve repair and implantation procedures, has broadened their applicability to a larger patient population, resulting in enhanced long-term survival [17,18]. Studies indicate a significant increase, approximately 5-fold for transcatheter aortic valve replacements and 10-fold for mitral valve replacements, in the past five years [19]. Additionally, early intervention, even among asymptomatic patients with severe VHD, has further reduced mortality rates and emphasized the need for novel population-based screening approaches [20]. However, it is crucial to note that despite these advancements, disparities in VHD mortality persist among specific demographic groups.

Our study findings indicate that mortality rates related to VHD remained stable or slightly increased until 2014 among older women and men, respectively, after which a consistent decline was observed. However, males consistently exhibited a higher mortality rate associated with VHD compared to females throughout this timeframe. This discrepancy can be attributed to a greater prevalence of concurrent risk factors in males, such as coronary artery disease (CAD), diabetes, hypertension (HTN), and smoking [21]. Additionally, delayed diagnosis also leads to females being under-referred for surgical or transcatheter valve repair procedures [22,23]. Interestingly, females, despite having worse short-term postoperative outcomes compared to men, tend to exhibit equal or even better long-term survival after treatment procedures, largely due to their longer life expectancy [24,25]. All these factors contribute to the higher prevalence of VHD in males and perpetuate the gender-based differences in VHD awareness and screening.

Furthermore, white patients with VHD had a higher mortality rate compared to other racial groups. This trend persisted despite an overall decline in mortality across different races throughout the study period. Although some studies have reported a lower prevalence of aortic stenosis in patients from racial and ethnic minorities compared to white patients, the differences in manifestation and presentation of aortic stenosis do not fully explain the variation in mortality [26]. Historically, racial and ethnic minorities have faced reduced access to diagnostic imaging and cardiac procedures, which may explain the disparities in prevalence based on hospital data [27,28]. These disparities in access could be attributed to financial constraints and potential implicit biases affecting referrals for VHD diagnosis and treatment. Additionally, the ability of primary care providers to identify which patients would benefit from screening echocardiography is low, as evidenced by a study from Brazil [29].

Significant healthcare disparities exist among racial and ethnic groups when it comes to the utilization of VHD surgical and transcatheter treatments, along with other structural heart interventions [28,30]. The reasons for the low utilization among racial and ethnic minorities are likely multifaceted, involving factors at the patient, provider, and healthcare system levels [31]. Ineffective patient communication and a lack of racial concordance may contribute to this issue, underscoring the importance of having a diverse physician workforce [32]. Thus, the underdiagnosis and lower referral rates among racial and ethnic minorities not only lead to underutilization of treatment procedures within those communities but also contribute to elevated VHD prevalence and, hence, mortality rates among the white population [33]. Addressing these disparities within institutions and implementing culturally tailored, multidisciplinary interventions may help mitigate the racial disparities observed in VHD-related mortality among adults.

In metropolitan regions, the AAMR linked to valvular heart disease has decreased over the last two decades. Conversely, there was a rise in VHD-related AAMR in non-metropolitan areas until 2015, but this was succeeded by a consistent decrease in recent years. Interestingly, nonmetropolitan areas have consistently maintained a higher AAMR than their metropolitan counterparts throughout the study period. This disparity can be attributed to several factors, including lower socioeconomic status in rural regions and a shortage of primary care physicians and cardiologists. Between 2002 and 2015, the number of primary care physicians declined at a rate twice as high in nonmetropolitan areas compared to urban areas [34]. The closure of a significant number of hospitals over the past decade further compounds these disparities. These regional differences may also be influenced by inconsistencies in outpatient cardiology practices, such as variations in the implementation of guideline-directed therapies, the impact of state regulations on Medicaid, restricted access to quality healthcare, a higher burden of comorbidities, and a prevalence of sedentary lifestyles [35]. These findings emphasize the need for extensive population-based studies in these regions to identify the primary factors contributing to these disparities.

One potential solution to address these issues is the establishment of a cloud-based image repository that utilizes standardized tools for communication between big academic setups and referring centers. This approach can expedite physician decision-making, enhance communication, and reduce patients' travel burden. Additionally, the implementation of a robust e-consult platform can provide comprehensive care for patients with VHD, covering consultations and follow-up care, thus addressing concerns about fragmented care [36].

Globally, rheumatic heart disease (RHD) is the most common valve pathology, whereas in developed countries like the US, degenerative non-rheumatic VHD prevails [37]. Our findings show that mortality rates related to VHD either remained stable or decreased during most of the study period for both non-rheumatic and rheumatic VHDs. However, our analysis revealed higher mortality rates from non-rheumatic VHDs compared to the rheumatic group in the US. Several factors could underlie this observation. Firstly, improved healthcare and longer life expectancy have led to an aging population with an increased incidence of degenerative valve diseases such as calcific aortic valve stenosis and degenerative mitral valve regurgitation [38]. Secondly, lifestyle changes have raised the prevalence of risk factors like hypertension, hyperlipidemia, diabetes, and smoking, contributing to the development and progression of non-rheumatic VHDs [38]. Thirdly, advancements in diagnostic methods like echocardiography enable earlier detection and diagnosis of non-rheumatic VHDs, resulting in higher reported mortality rates [[12], [13], [14], [15], [16]]. Moreover, the decline in rheumatic fever (RF) due to better healthcare practices and widespread antibiotic use has reduced the incidence of rheumatic VHDs [37]. Additionally, studies suggest a higher prevalence of coronary artery disease (CAD) in non-rheumatic VHDs, further increasing mortality rates in this group [38]. These factors collectively underscore the epidemiological shift towards non-rheumatic VHDs as a major cause of mortality in the US.

Despite an overall decline in mortality rates associated with aortic and mitral valve disorders over the past two decades, our analysis has indicated that deaths related to AVDs in the US exceed those associated with MVDs. Several factors could account for this difference. Firstly, AVD, especially aortic stenosis (AS), has a higher incidence and prevalence compared to MVD, primarily because they often result from age-related degenerative changes [38]. For instance, the prevalence of AS increases significantly with age, estimated at 0.2 % before the age of 65 and 2.8 % after 75 [39]. Conversely, MVD usually has multiple etiologies, including degenerative changes, RF, and congenital abnormalities, with RHD being a major contributor to mitral stenosis in older patients [40]. Secondly, well-established risk factors for aortic valve disorders, such as hypercholesterolemia, hypertension, and diabetes, are common comorbidities among the aging population in the US, predisposing individuals to the development and faster progression of AS [40]. Additionally, AVD is associated with potentially life-threatening complications like aortic dissection and left ventricular dysfunction, which may contribute to higher mortality rates. Nonetheless, in recent years, timely interventions and advancements in surgical and percutaneous valve repair procedures might account for decreased mortality rates associated with both aortic and mitral valve disorders [[17], [18], [19], [20]].

Similarly, our study showed a general decrease in mortality rates linked to VHD across both age categories. Additionally, our findings revealed higher VHD-related AAMRs in the older age bracket (≥75 years) compared to the younger group (<75 years) consistently throughout the study period. This can be attributed to the natural aging process. As individuals age, they are more likely to develop degenerative changes in the heart valves, such as calcification and fibrosis, leading to the development of VHD [38]. Furthermore, older individuals often have comorbidities such as hypertension, diabetes, and CAD, which further increase their risk of developing VHD and experiencing adverse outcomes [41]. However, the advancements in medical treatment, including the use of medications like statins, antiplatelet agents, and antihypertensives, and improved management of associated risk factors through public health initiatives like healthy eating campaigns, smoking cessation, and exercise programs, have led to better disease control, and patient outcomes [16,20]. These combined efforts might account for the notable decline in mortality associated with VHD in recent years, especially in the younger population.

4.1 Limitations

This study has several limitations that warrant consideration. Firstly, the use of International Statistical Classification of Diseases codes (ICD-10) and reliance on death certificates introduces the potential for errors in classifying or omitting VHD as a cause of death [42]. Moreover, IE was not specifically evaluated in our analysis as a cause of death. These discrepancies in diagnosis and disease classification can impact mortality data. Secondly, we employed Age-Adjusted Mortality Rates (AAMRs) per 1,000,000 individuals to analyze deaths attributed to VHD across distinct age brackets (≥75 years vs. < 75 years) due to insufficient data from the CDC regarding AAMRs per 100,000 individuals. Thirdly, the database lacks essential clinical variables that could provide a more comprehensive description of disease characteristics. These variables include details about the specific VHD phenotype, vital signs, laboratory results, ejection fraction, genetic analysis, and imaging data, which are critical for a thorough understanding of the disease phenotype, its severity, and the presence of factors that affect prognosis. Additionally, the rise in electronic health record diagnosis of VHD may lead to increased reporting of VHD-related deaths on death certificates. Furthermore, the database does not contain information on the treatments received by individuals, such as medical therapies, valvular repair, and implantation by surgical or percutaneous approaches. Lastly, it lacks data related to social and economic determinants of health, which can significantly impact access to healthcare and, subsequently, influence mortality rates among different demographic groups.

5 Conclusion

Our study revealed a decline in VHD mortality in the United States from 1999 to 2019. Nevertheless, disparities persist, particularly concerning gender, race, age, geographic regions, and the type of VHD. Notably, White adults, males, and older adults (≥75 years), nonmetropolitan areas, non-rheumatic VHD, and AVDS exhibited the highest age-adjusted mortality rates. Addressing these disparities requires targeted health policies aimed at reducing VHD mortality equitably, emphasizing prevention, early diagnosis, and prompt referrals.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Eman Ali: Conceptualization, Data curation, Formal analysis. Yusra Mashkoor: Data curation, Formal analysis, Writing – original draft. Fakhar Latif: Data curation, Resources, Software. Fnu Zafrullah: Methodology, Software, Writing – original draft. Waleed Alruwaili: Data curation, Formal analysis, Resources. Sameh Nassar: Software, Visualization, Writing – original draft. Karthik Gonuguntla: Methodology, Validation, Writing – original draft. Harshith Thyagaturu: Data curation, Investigation, Writing – original draft. Mohammad Kawsara: Supervision, Validation, Visualization, Writing – review & editing. Ramesh Daggubati: Data curation, Software, Writing – review & editing. Yasar Sattar: Conceptualization, Project administration, Writing – review & editing. Muhammad Sohaib Asghar: Formal analysis, Supervision, Writing – review & editing.

Declaration of competing interest

None of the authors have any financial or industrial conflict of interest.

Appendix A Supplementary data

The following is the Supplementary data to this article:Multimedia component 1

Multimedia component 1

Acknowledgements

None.

Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijcrp.2024.200321.
==== Refs
References

1 Otto C.M. Bonow R.O. Valvular Heart Disease: A Companion to Braunwald's Heart Disease fifth ed. 2021 Elsevier
2 Carabello B.A. Crawford F.A. Valvular heart disease N. Engl. J. Med. 337 1 1997 32 41 10.1056/NEJM199707033370107 9203430
3 Velkoff Victoria A.V. Grayson K. The Next Four Decades: the Older Population in the United States: 2010 to 2050 2010 United States Census Bureau https://www.census.gov/library/publications/2010/demo/p25-1138.html
4 Osnabrugge R.L.J. Mylotte D. Head S.J. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study J. Am. Coll. Cardiol. 62 11 2013 1002 1012 10.1016/j.jacc.2013.05.015 23727214
5 Leon M.B. Smith C.R. Mack M. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery N. Engl. J. Med. 363 17 2010 1597 1607 10.1056/NEJMoa1008232 20961243
6 National Center for Health Statistics, CDC About underlying cause of death 1999–2018 https://wonder.cdc.gov/ucd-icd10.html
7 Cross S.H. Kaufman B.G. Mentz R.J. Kamal A.H. Taylor D.H. Warraich H.J. Trends in place of death for individuals with cardiovascular disease in the United States J. Am. Coll. Cardiol. 74 15 2019 1943 1946 10.1016/j.jacc.2019.08.1015 31601374
8 Cross S.H. Mehra M.R. Bhatt D.L. Rural-urban differences in cardiovascular mortality in the US, 1999-2017 JAMA 323 18 2020 1852 1854 10.1001/jama.2020.2047 32396176
9 Barco S. Mahmoudpour S.H. Valerio L. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database Lancet Respir. Med. 8 3 2020 277 287 10.1016/S2213-2600(19)30354-6 31615719
10 Woolf S.H. Schoomaker H. Life expectancy and mortality rates in the United States, 1959-2017 JAMA 322 20 2019 1996 2016 10.1001/jama.2019.16932 31769830
11 Lmj A. Shakirat O. Rodrigo B. Oc M. Valvular heart disease in relation to race and ethnicity J. Am. Coll. Cardiol. 78 24 2021 2493 2504 10.1016/j.jacc.2021.04.109 34886971
12 Yang Y. Xiao B. Feng X. Identification of hub genes and key signaling pathways by weighted gene co-expression network analysis for human aortic stenosis and insufficiency Front Cardiovasc Med 10 2023 https://www.frontiersin.org/articles/10.3389/fcvm.2023.857578
13 Liu Q. Yu Y. Xi R. Association between lipoprotein(a) and calcific aortic valve disease: a systematic review and meta-analysis Front Cardiovasc Med 9 2022 https://www.frontiersin.org/articles/10.3389/fcvm.2022.877140
14 Michelena H.I. Prakash S.K. Della Corte A. Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon) Circulation 129 25 2014 2691 2704 10.1161/CIRCULATIONAHA.113.007851 24958752
15 Kwon J. Lee S.Y. Jeon K. Deep learning–based algorithm for detecting aortic stenosis using electrocardiography J. Am. Heart Assoc. 9 7 2020 10.1161/JAHA.119.014717
16 d'Arcy J.L. Coffey S. Loudon M.A. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study Eur. Heart J. 37 47 2016 3515 3522 10.1093/eurheartj/ehw229 27354049
17 Annabi M.S. Côté N. Dahou A. Comparison of early surgical or transcatheter aortic valve replacement versus conservative management in low-flow, low-gradient aortic stenosis using inverse probability of treatment weighting: results from the TOPAS prospective observational cohort study J. Am. Heart Assoc. 9 24 2020 e017870 10.1161/JAHA.120.017870
18 Muller D.W.M. Sorajja P. Duncan A. 2-Year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation J. Am. Coll. Cardiol. 78 19 2021 1847 1859 10.1016/j.jacc.2021.08.060 34736561
19 Davidson L.J. Davidson C.J. Transcatheter treatment of valvular heart disease: a review JAMA 325 24 2021 2480 2494 10.1001/jama.2021.2133 34156404
20 Ismayl M. Machanahalli Balakrishna A. Abusnina W. Surgical aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis: an updated systematic review and meta-analysis Cardiovasc. Revascularization Med. 42 2022 36 44 10.1016/j.carrev.2022.03.001
21 Matta A. Moussallem N. Coronary artery disease is associated with valvular heart disease, but could it Be a predictive factor? Indian Heart J. 71 3 2019 284 287 10.1016/j.ihj.2019.07.001 31543203
22 Nitsche C. Koschutnik M. Kammerlander A. Hengstenberg C. Mascherbauer J. Gender-specific differences in valvular heart disease Wien Klin. Wochenschr. 132 3–4 2020 61 68 10.1007/s00508-019-01603-x 31997064
23 DesJardin J.T. Chikwe J. Hahn R.T. Hung J.W. Delling F.N. Sex differences and similarities in valvular heart disease Circ. Res. 130 4 2022 455 473 10.1161/CIRCRESAHA.121.319914 35175844
24 Fuchs C. Mascherbauer J. Rosenhek R. Gender differences in clinical presentation and surgical outcome of aortic stenosis Heart 96 7 2010 539 545 10.1136/hrt.2009.186650 20350991
25 Onorati F. D'Errigo P. Barbanti M. Different impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: results of the multicenter Italian OBSERVANT Registry J. Thorac. Cardiovasc. Surg. 147 5 2014 1529 1539 10.1016/j.jtcvs.2013.05.039 23856202
26 Patel D. Green K.D. Fudim M. Harrell F.E. Wang T.J. Robbins M.A. Racial differences in the prevalence of aortic stenosis J. Am. Heart Assoc. 3 2014 e000879
27 Ross A.B. Kalia V. Chan B.Y. Li G. The influence of patient race on the use of diagnostic imaging in United States emergency departments: data from the National Hospital Ambulatory Medical Care survey BMC Health Serv. Res. 20 1 2020 840 10.1186/s12913-020-05698-1 32894129
28 Alkhouli M. Alqahtani F. Holmes D.R. Berzingi C. Racial disparities in the utilization and outcomes of structural heart disease interventions in the United States J. Am. Heart Assoc. 8 15 2019 10.1161/JAHA.119.012125
29 Nascimento B.R. Beaton A.Z. Nunes M.C.P. Integration of echocardiographic screening by non-physicians with remote reading in primary care Heart 105 4 2019 283 LP 290 10.1136/heartjnl-2018-313593 30181202
30 Wj B. Jl R. Uf E. Racial and ethnic differences in treatment and outcomes of severe aortic stenosis JACC Cardiovasc. Interv. 13 2 2020 149 156 10.1016/j.jcin.2019.08.056 31973792
31 Fryar C.D. Chen T.C. Li X. Prevalence of Uncontrolled Risk Factors for Cardiovascular Disease: United States, 1999-2010 2012 US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics
32 Saha S. Beach M.C. Impact of physician race on patient decision-making and ratings of physicians: a randomized experiment using video vignettes J. Gen. Intern. Med. 35 4 2020 1084 1091 10.1007/s11606-020-05646-z 31965527
33 Sleder A. Tackett S. Cerasale M. Socioeconomic and racial disparities: a case-control study of patients receiving transcatheter aortic valve replacement for severe aortic stenosis J racial Ethn Health disparities 4 6 2017 1189 1194 10.1007/s40615-016-0325-x 28039604
34 Basu S. Berkowitz S.A. Phillips R.L. Bitton A. Landon B.E. Phillips R.S. Association of primary care physician supply with population mortality in the United States, 2005-2015 JAMA Intern. Med. 179 4 2019 506 514 10.1001/jamainternmed.2018.7624 30776056
35 Glynn P.A. Molsberry R. Harrington K. Geographic variation in trends and disparities in heart failure mortality in the United States, 1999 to 2017 J. Am. Heart Assoc. 10 9 2021 10.1161/JAHA.120.020541
36 Optimizing systems of care for valve disease https://www.acc.org/latest-in-cardiology/articles/2017/02/16/13/33/optimizing-systems-of-care-for-valve-disease
37 Aluru J.S. Barsouk A. Saginala K. Rawla P. Barsouk A. Valvular heart disease Epidemiology Med. Sci. 10 2 2022 32 10.3390/medsci10020032 Published 2022 Jun 15
38 Kruczan D.D. Silva N.A. Pereira Bde B. Romão V.A. Correa Filho W.B. Morales F.E. Coronary artery disease in patients with rheumatic and non-rheumatic valvular heart disease treated at a public hospital in Rio de Janeiro Arq. Bras. Cardiol. 90 3 2008 197 203 10.1590/s0066-782x2008000300010 18392400
39 Grave C. Juillière Y. Tuppin P. Epidemiological features of aortic stenosis in a French nationwide study: 10-year trends and New challenges J. Am. Heart Assoc. 9 23 2020 e017588 10.1161/JAHA.120.017588
40 Santangelo G. Bursi F. Faggiano A. The global burden of valvular heart disease: from clinical Epidemiology to management J. Clin. Med. 12 6 2023 2178 10.3390/jcm12062178 Published 2023 Mar 10 36983180
41 Song F. Liu F.Z. Liang Y.F. Clinical, sonographic characteristics and long-term prognosis of valvular heart disease in elderly patients J Geriatr Cardiol 16 1 2019 33 41 10.11909/j.issn.1671-5411.2019.01.007 30800149
42 Coady S.A. Sorlie P.D. Cooper L.S. Folsom A.R. Rosamond W.D. Conwill D.E. Validation of death certificate diagnosis for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study J. Clin. Epidemiol. 54 1 2001 40 50 10.1016/S0895-4356(00)00272-9 11165467
